🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs
1,344

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,344 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 17 of 28

  1. JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)

    Shanghai University of Traditional Chinese Medicine

    Diffuse Large B Cell Lymphoma

    phase 1 mab completed

    1 trial

  2. JZP341

    Jazz Pharmaceuticals Ireland Limited

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  3. JZP815

    Jazz Pharmaceuticals Ireland Limited

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  4. JZP898

    Jazz Pharmaceuticals Ireland Limited

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  5. Jakavi 10 mg tablets, CELECOXIB , Navitoclax, Navitoclax, Jakavi 10 mg tablets, Jakavi 5 mg tablets, Jakavi 5 mg tablets, Jakavi 5 mg tablets, Jakavi 10 mg tablets

    AbbVie Deutschland GmbH & Co. KG

    Myelofibrosis, Myeloproliferative Neoplasms

    phase 1 small molecule active

    1 trial

  6. Jiu-wei-zhen-xiao Granule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 1 small molecule completed

    1 trial

  7. KCP-330

    Karyopharm Therapeutics Inc

    Sarcoma

    phase 1 small molecule completed

    1 trial

  8. KFA115

    Novartis Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule active

    1 trial

  9. KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer

    Boehringer Ingelheim

    G12D/G12V Pancreatic Ductal Adenocarcinoma

    phase 1 other active

    1 trial

  10. KK-LC-1 TCR-T cells

    Iovance Biotherapeutics B.V.

    Gastric Cancer

    phase 1 mab active

    1 trial

  11. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    Kura Oncology

    Pancreatic Ductal Adeno Carcinoma, Colorectal Cancer, Non- Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma

    phase 1 other active

    1 trial

  12. KO-947

    Kura Oncology

    Advanced Malignant Neoplasm

    phase 1 small molecule terminated

    1 trial

  13. KPT-330

    Karyopharm Therapeutics Inc

    Diffuse Large B-Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  14. KPT-330

    Karyopharm Therapeutics Inc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  15. KPT-330

    Karyopharm Therapeutics Inc

    Relapsed Acute Lymphoblastic Leukemia (ALL)

    phase 1 small molecule active

    1 trial

  16. KPT-9274

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia

    phase 1 small molecule completed

    1 trial

  17. KPT-9274

    Karyopharm Therapeutics Inc

    Solid Tumors

    phase 1 small molecule terminated

    1 trial

  18. KRAS Vaccine with Poly-ICLC adjuvant

    United Therapeutics Europe Ltd

    Colorectal Cancer

    phase 1 small molecule active

    1 trial

  19. KSH01 injection

    TScan Therapeutics

    Solid Tumor

    phase 1 small molecule active

    1 trial

  20. KSV01 Injection

    TScan Therapeutics

    Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  21. KT-333

    Kymera Therapeutics

    Non Hodgkin Lymphoma (NHL)

    phase 1 small molecule completed

    1 trial

  22. KT-413

    Kymera Therapeutics

    Non Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial

  23. KXV01 TCR Lentinvivo Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  24. KXV01 TCR Lentinvivo Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Cancer

    phase 1 small molecule active

    1 trial

  25. KXV01 TCR Lentinvivo Injection

    TScan Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule active

    2 trials

  26. LB-100 for Injection

    LIXTE BIOTECHNOLOGY HOLDINGS, INC.

    Tumors

    phase 1 small molecule completed

    1 trial

  27. LB1901

    Nanjing Legend Biotech Co.

    T-Cell Lymphoma

    phase 1 mab active

    1 trial

  28. LB1908

    Nanjing Legend Biotech Co.

    Gastric Cancer

    phase 1 mab active

    1 trial

  29. LB2102

    Nanjing Legend Biotech Co.

    Small Cell Lung Cancer Extensive Stage

    phase 1 mab active

    1 trial

  30. LCAR-AIO Cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphocytic Leukemia

    phase 1 mab terminated

    1 trial

  31. LCAR-AIO cells product

    Nanjing Legend Biotech Co.

    B-cell Lymphoma Recurrent

    phase 1 mab terminated

    1 trial

  32. LCAR-AMDR Cells Product

    Nanjing Legend Biotech Co.

    Acute Myeloid Leukemia

    phase 1 mab terminated

    1 trial

  33. LCAR-C182A cells

    Nanjing Legend Biotech Co.

    Gastric Cancer

    phase 1 mab terminated

    1 trial

  34. LCAR-C18S cells

    Nanjing Legend Biotech Co.

    Solid Tumors, Adult

    phase 1 mab terminated

    1 trial

  35. LCAR-G08 cells

    Nanjing Legend Biotech Co.

    Advanced Gastrointestinal Tumors

    phase 1 mab terminated

    1 trial

  36. LCAR-HL30 cells

    Nanjing Legend Biotech Co.

    Hodgkin's Lymphoma

    phase 1 mab active

    1 trial

  37. LCAR-M23 cells

    Nanjing Legend Biotech Co.

    Epithelial Ovarian Cancer

    phase 1 mab terminated

    1 trial

  38. LDK378

    Novartis Pharmaceuticals

    Anaplastic Lymphoma Kinase (ALK)

    phase 1 small molecule completed

    1 trial

  39. LEE011

    Novartis Pharmaceuticals

    Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

    phase 1 small molecule completed

    1 trial

  40. LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules, Bavencio 20 mg/mL concentrate for solution for infusion, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules

    Merck Sharp and Dohme

    Central Nervous System Tumors

    phase 1 small molecule active

    1 trial

  41. LENVIMA 4 mg hard capsules, volrustomig, Kisplyx 10 mg hard capsules, Kisplyx 4 mg hard capsules, LENVIMA 10 mg hard capsules

    AstraZeneca AB

    Advanced Renal Cell Carcinoma

    phase 1 small molecule active

    1 trial

  42. LN-144

    Iovance Biotherapeutics B.V.

    Stage IIIB Melanoma

    phase 1 mab terminated

    1 trial

  43. LN-145/LN-144

    Iovance Biotherapeutics B.V.

    Soft Tissue Sarcoma

    phase 1 mab active

    1 trial

  44. LUCAR-20S CAR-T cells

    Nanjing Legend Biotech Co.

    Diffuse Large B Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  45. LUCAR-20SP cells

    Nanjing Legend Biotech Co.

    Relapsed B-cell Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  46. LUCAR-E9D or LUCAR-E9K cells product

    The First People's Hospital of Lianyungang

    B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory

    phase 1 mab active

    1 trial

  47. LUCAR-G39D cells product

    Nanjing Legend Biotech Co.

    B-Cell Non-Hodgkin Lymphoma-Recurrent

    phase 1 mab active

    1 trial

  48. LUCAR-G39P cells product

    The First People's Hospital of Lianyungang

    Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 mab terminated

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,344 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.